Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Skinosive has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is being handled by 1 distinct examiner in 1 distinct art unit. This indicates a highly concentrated interaction with the patent office, with no current distribution of cases across different officials or departments.
ARNOLD, ERNST V is the busiest examiner for this portfolio, currently managing 1 pending office action. Because the total pending actions for the company is 1, this examiner is in charge of the entire active workload. This concentration suggests that the prosecution results for the current portfolio are entirely dependent on the review of this single individual. There are no other active matters to provide alternative examiner perspectives.
The involvement of 1 distinct art unit for the 1 pending office action confirms a narrow administrative focus for the current filings. Practitioners should note that there is no diversification of examiner perspectives within the Biotechnology & Pharmaceuticals area for this portfolio. The workload is entirely centralized under ARNOLD, ERNST V, which simplifies the management of the company's active patent matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637828 | BIOADHESIVE PARTICLES COMPRISING ACTIVE AGENTS, AND USES THEREOF | ARNOLD, ERNST V | 11d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637828 | BIOADHESIVE PARTICLES COMPRISING ACTIVE AGENTS, AND USES THEREOF | ARNOLD, ERNST V | 11d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17637828 | BIOADHESIVE PARTICLES COMPRISING ACTIVE AGENTS, AND USES THEREOF | ARNOLD, ERNST V | 1613 | §103§112 | Final Rejection | 11d overdue | Pending | Feb 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSkinosive has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ernst V Arnold has the most, with 1 of Skinosive's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
